List view / Grid view
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
A new study demonstrates how neurotransmitters affect brain gene expression, offering potential therapeutic insights for circadian rhythm disorders.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
A new deep-learning method could enhance therapeutic devices for people with neurological or mental health conditions.
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
Monoamine oxidase inhibitors can block the function of a protein, helping T cells to effectively fight cancer, a study in mice has shown.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
